Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.33 |
| ▸ | TUBB | P07437 | 1/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.33 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.33 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.33 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.33 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.33 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.33 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733531 | 0.78 | TUBB4A (0.51) | KCNJ1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL252784 | 0.74 | GAA (0.39) | KCNJ1ALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL934205 | 0.74 | NQO1 (0.48) | KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL31621333 | 0.73 | ALDH1A1 (0.53) | KCNJ1KDM4EALDH1A1MAPTLMNA | |
| SCHEMBL102267 | 0.73 | ALDH1A3 (0.53) | KCNJ1ALDH1A1SMN1; SMN2 | |
| SCHEMBL31141577 | 0.73 | KCNJ1 (0.36) | KCNJ1CCR1TUBB4ATUBBTUBA3C | |
| SCHEMBL12721565 | 0.73 | NPC1 (0.39) | KCNJ1L3MBTL1 | |
| SCHEMBL20489794 | 0.73 | DRD1 (0.49) | KCNJ1CCR1KDM4EALDH1A1LMNA | |
| SCHEMBL31174798 | 0.73 | NPC1 (0.39) | KCNJ1L3MBTL1 | |
| SCHEMBL510017 | 0.73 | LTA4H (0.44) | KDM4EALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2025-05-29 | — | — | US | disclosed |
| US-12168015-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-12168016-B2 | Aryl-OR heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-12161645-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240277723-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2024-08-22 | — | — | US | disclosed |
| US-20240245698-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2024-07-25 | — | — | US | disclosed |
| US-20240245697-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2024-07-25 | — | — | US | disclosed |
| EP-4360712-A2 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-3943485-B1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-3943485-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-9090562-B2 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9040572-B2 | Method of preparing benzoimidazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-26 | — | — | US | disclosed |
| US-20140288041-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8765732-B2 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2697199-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| US-20130231477-A1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-09-05 | — | — | US | disclosed |
| EP-2621915-A2 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | Daewoong Pharmaceutical Co., Ltd (KR) | 2013-08-07 | — | — | EP | disclosed |
| US-20130123234-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-16 | — | — | US | disclosed |
| WO-2012142504-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012044043-A2 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168016-B2 | Aryl-OR heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | KCNJ1 1158/4885CCR1 831/4885TUBB4A 1792/4885 |
| US-20240245698-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | KCNJ1 1158/4885CCR1 831/4885TUBB4A 1792/4885 |
| US-20240277723-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | KCNJ1 1158/4885CCR1 831/4885TUBB4A 1792/4885 |
| US-12161645-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | KCNJ1 1158/4885CCR1 831/4885TUBB4A 1792/4885 |
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | KCNJ1 1158/4885CCR1 831/4885TUBB4A 1792/4885 |
| US-20240245697-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | KCNJ1 1158/4885CCR1 831/4885TUBB4A 1792/4885 |
| US-20140288041-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | AHR, ARNT, CYP1B1 | KCNJ1 1158/4885CCR1 831/4885TUBB4A 1792/4885 |
| US-20130231477-A1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | BRD1, BRD4, VAT1 | KCNJ1 73/4885CCR1 3598/4885TUBB4A 2857/4885 |
| US-20130123234-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | AHR, ARNT, CYP1B1 | KCNJ1 1158/4885CCR1 831/4885TUBB4A 1792/4885 |
| US-12168015-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | KCNJ1 1158/4885CCR1 831/4885TUBB4A 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.